Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback